Amgen And UCB Resubmit Biologics License Application (BLA) For Evenity (romosozumab) To The US FDA

Treatment for Osteoporosis

Amgen And UCB Resubmit Biologics License Application (BLA) For Evenity (romosozumab) To The US FDA